Chugai Pharmaceutical Co., Ltd.’s Evrysdi (risdiplam) is among the latest batch of new drug approvals in Japan, providing another option for spinal muscular atrophy (SMA) patients in the country. The survival motor neuron 2 (SMN2)-directed splicing modifier was granted orphan designation in March 2019 and filed for approval last October.
Attention is now turning to how the therapy will be priced under the national health insurance system, which will enable...






